ReviewJournal of mid-life health
Premature ovarian insufficiency: Pathogenesis and management.
Review in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of acupuncture on patients with premature ovarian insufficiency and polycystic ovary syndrome: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2024Pooled it
- Mesenchymal stem cells and platelet rich plasma in the treatment of premature ovarian insufficiency: a scoping review.Contraception and reproductive medicine · 2025Review
- Unveiling the Impact of COVID-19 on Ovarian Function and Premature Ovarian Insufficiency: A Systematic Review.Biomedicines · 2025Review
- Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities.Stem cell research & therapy · 2024Review
- Review
- Protective role of stem cells in POI: Current status and mechanism of action, a review article.Heliyon · 2024Review
- The Role of Lifestyle and Dietary Factors in the Development of Premature Ovarian Insufficiency.Antioxidants (Basel, Switzerland) · 2023Review
- Progesterone from ovulatory menstrual cycles is an important cause of breast cancer.Breast cancer research : BCR · 2023Review
- Human Pluripotent Stem Cell-Mesenchymal Stem Cell-Derived Exosomes Promote Ovarian Granulosa Cell Proliferation and Attenuate Cell Apoptosis Induced by Cyclophosphamide in a POI-like Mouse Model.Molecules (Basel, Switzerland) · 2023Article
- Whole exome sequencing reveals novel variants associated with diminished ovarian reserve in young women.Frontiers in genetics · 2023Article
- Ovarian Reserve Disorders, Can We Prevent Them? A Review.International journal of molecular sciences · 2022Review
- Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022Review
- Female germline stem cells: aging and anti-aging.Journal of ovarian research · 2022Review
- Does the Value of FSH Predict Severity of Metabolic Complications in Females with POI?Journal of clinical medicine · 2022Article
- Chrysin reduces inflammation and oxidative stress and improves ovarian function in D-gal-induced premature ovarian failure.Bioengineered · 2022Article
- Translation regulatory long non-coding RNA 1 (TRERNA1) sponges microRNA-23a to suppress granulosa cell apoptosis in premature ovarian failure.Bioengineered · 2022Article
- The relationship between genetic variants associated with primary ovarian insufficiency and lipid profile in women recruited from MASHAD cohort study.BMC women's health · 2022Article
- A new approach of using platelet-rich autologous plasma to increase the ovarian reservoir in a Syrian patient with ovarian insufficiency: A case report.Annals of medicine and surgery (2012) · 2022Article
- Maturity-onset diabetes of the young type 3 and premature ovarian insufficiency: chance or causality: a case report and literature review.Endocrinology, diabetes & metabolism case reports · 2022Article
- The impact of herbal medicine in regulating intestinal flora on female reproductive disorders.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term premature ovarian insufficiency (POI) describes a continuum of declining ovarian function in a young woman, resulting in an earlier than average menopause. It is a term that reflects the variable nature of the condition and is substantially less emotive than the formerly used "premature ovarian failure" which signaled a single event in time. Contrary to the decline in the age of menarche seen over the last 3-4 decades there has been no similar change in the age of menopause. In developed nations, the average age for cessation of menstrual cycles is 50-52 years. The age is younger among women from developing nations. Much has been written about POI despite a lack of good data on the incidence of this condition. It is believed that 1% of women under the age of 40 years and 0.1% under the age of 30 years will develop POI. Research is increasingly providing information about the pathogenesis and treatments are being developed to better preserve ovarian function during cancer treatment and to improve fertility options. This narrative review summarizes the current literature to provide an approach to best practice management of POI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.